Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revamped Lundbeck Ups Outlook Amid Strong Brintellix and Rexulti Sales

Executive Summary

The rebounding Danish CNS specialist raised its 2016 revenue and profit forecasts as it continued to benefit from an ongoing structuring and buoyant sales in the US market, notably for its drugs Brintellix and Rexulti.

Advertisement

Related Content

Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test
Lundbeck Restructures Around 5 Key Products; 1,000 Jobs To Go

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel